CGEM Cullinan Oncology, Inc. Stock Quote

CGEM [NASD]

Index	-	P/E	-	EPS (ttm)	-1.29	Insider Own	0.80%	Shs Outstand	43.30M	Perf Week	-11.16%
Market Cap	913.28M	Forward P/E	-	EPS next Y	-1.98	Insider Trans	-69.15%	Shs Float	35.54M	Perf Month	-6.17%
Income	-53.90M	PEG	-	EPS next Q	-0.42	Inst Own	74.20%	Short Float	7.30%	Perf Quarter	-11.37%
Sales	18.90M	P/S	48.32	EPS this Y	-150.80%	Inst Trans	0.03%	Short Ratio	10.89	Perf Half Y	-29.89%
Book/sh	10.52	P/B	2.11	EPS next Y	-52.30%	ROA	-17.20%	Target Price	-	Perf Year	-
Cash/sh	8.19	P/C	2.71	EPS next 5Y	-	ROE	-27.60%	52W Range	20.35 - 59.85	Perf YTD	-25.74%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-62.89%	Beta	-
Dividend %	-	Quick Ratio	60.00	Sales past 5Y	-	Gross Margin	-	52W Low	9.14%	ATR	1.63
Employees	24	Current Ratio	60.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	43.39	Volatility	8.64% 6.86%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-10.00%	Profit Margin	-	Rel Volume	0.56	Prev Close	23.42
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 10 BMO	Payout	-	Avg Volume	238.35K	Price	22.21
Recom	1.70	SMA20	-4.39%	SMA50	-14.30%	SMA200	-29.98%	Volume	132,433	Change	-5.17%

Apr-27-21

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$40

Feb-02-21

Initiated

SVB Leerink

Outperform

$52

Feb-02-21

Initiated

Morgan Stanley

Equal-Weight

$38

Feb-02-21

Initiated

Evercore ISI

Outperform

$55

Feb-01-21

Initiated

H.C. Wainwright

Buy

$47

Oct-18-21 07:00AM	Cullinan Oncology Appoints Nadim Ahmed as Chief Executive Officer GlobeNewswire -15.52%
Sep-08-21 04:01PM	Cullinan Oncology to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-16-21 06:44AM	We're Hopeful That Cullinan Oncology (NASDAQ:CGEM) Will Use Its Cash Wisely Simply Wall St.
Aug-10-21 06:30AM	Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2021 Financial Results GlobeNewswire +6.70%
Aug-05-21 04:05PM	Cullinan Oncology to Participate in the 41st Annual Canaccord Genuity Growth Conference GlobeNewswire +13.58%
Jul-19-21 07:56PM	Is Cullinan Oncology, Inc. (CGEM) A Good Stock To Buy? Insider Monkey
Jun-29-21 08:00AM	Cullinan Oncology Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors GlobeNewswire
Jun-07-21 10:57AM	Cullinan Gets FDA Investigational Clearance for Leukemia Drug TheStreet.com
09:26AM	Cullinan (CGEM) Rises on Promising Phase I Cancer Study Data Zacks
08:30AM	Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML GlobeNewswire
Jun-04-21 11:53AM	Why Cullinan Oncology Stock Is Skyrocketing Today Motley Fool +11.26%
09:00AM	Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearls CLN-081 in NSCLC EGFR Exon 20 Patients GlobeNewswire
May-21-21 08:00AM	Cullinan Oncology Announces Management Transition GlobeNewswire -10.59%
May-19-21 05:00PM	Cullinan Oncology to Provide CLN-081 Clinical Update at ASCO 2021 GlobeNewswire
May-14-21 06:30AM	Cullinan Oncology Reports First Quarter 2021 Financial Results GlobeNewswire
Apr-08-21 01:38AM	Are Insiders Buying Cullinan Oncology, Inc. (NASDAQ:CGEM) Stock? Simply Wall St.
Apr-07-21 10:08AM	Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-30-21 06:15AM	Cullinan Oncology Reports Full Year 2020 Financial Results and Business Highlights GlobeNewswire
Mar-02-21 09:48AM	Cullinan Oncology, Inc. to Participate in the H.C. Wainwright Global Life Sciences Conference GlobeNewswire +8.06%
Feb-22-21 07:30AM	Cullinan Management, Inc. Announces Business Update GlobeNewswire
Jan-12-21 09:43PM	Cullinan Management Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +5.68%
Jan-08-21 12:13AM	Cullinan Management Announces Pricing of Upsized Initial Public Offering (CORRECTION) GlobeNewswire
Jan-07-21 09:03PM	Cullinan Management Announces Pricing of Upsized Initial Public Offering GlobeNewswire

Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Management, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Michaelson Jennifer	See Remarks	Oct 18	Option Exercise	4.30	4,000	17,200	26,911	Oct 20 04:30 PM
Michaelson Jennifer	See Remarks	Oct 18	Sale	21.42	4,000	85,669	22,911	Oct 20 04:30 PM
Trigilio Jeffrey	Chief Financial Officer	Oct 15	Option Exercise	4.30	8,000	34,400	10,250	Oct 18 04:15 PM
Zawel Leigh	See Remarks	Oct 15	Sale	25.00	19,574	489,350	37,285	Oct 18 04:15 PM
Trigilio Jeffrey	Chief Financial Officer	Oct 15	Sale	25.00	8,000	200,000	2,250	Oct 18 04:15 PM
Zawel Leigh	See Remarks	Oct 07	Sale	25.00	1,079	26,975	56,859	Oct 12 04:30 PM
Michaelson Jennifer	See Remarks	Sep 20	Option Exercise	4.30	4,000	17,200	26,911	Sep 21 04:30 PM
Zawel Leigh	See Remarks	Sep 20	Sale	25.16	7,468	187,895	57,938	Sep 21 04:30 PM
Michaelson Jennifer	See Remarks	Sep 20	Sale	24.51	4,000	98,048	22,911	Sep 21 04:30 PM
UBS Oncology Impact Fund L.P.	10% Owner	Sep 16	Sale	29.06	3,124	90,783	7,648,268	Sep 20 05:31 PM
GADICKE ANSBERT	Director	Sep 16	Sale	29.06	3,124	90,783	7,648,268	Sep 20 05:30 PM
GADICKE ANSBERT	Director	Sep 16	Sale	29.06	432	12,554	244,551	Sep 20 05:30 PM
UBS Oncology Impact Fund L.P.	10% Owner	Sep 15	Sale	29.16	6,425	187,353	7,651,392	Sep 16 04:45 PM
GADICKE ANSBERT	Director	Sep 15	Sale	29.16	6,425	187,353	7,651,392	Sep 16 04:44 PM
GADICKE ANSBERT	Director	Sep 15	Sale	29.16	888	25,894	244,983	Sep 16 04:44 PM
GADICKE ANSBERT	Director	Sep 14	Sale	29.17	7,106	207,282	7,657,817	Sep 16 04:44 PM
GADICKE ANSBERT	Director	Sep 14	Sale	29.17	982	28,645	245,871	Sep 16 04:44 PM
UBS Oncology Impact Fund L.P.	10% Owner	Sep 14	Sale	29.17	7,106	207,282	7,657,817	Sep 16 04:45 PM
UBS Oncology Impact Fund L.P.	10% Owner	Sep 13	Sale	29.10	3,595	104,614	7,664,923	Sep 13 06:24 PM
GADICKE ANSBERT	Director	Sep 13	Sale	29.10	3,595	104,614	7,664,923	Sep 13 06:22 PM
GADICKE ANSBERT	Director	Sep 13	Sale	29.10	497	14,463	246,853	Sep 13 06:22 PM
GADICKE ANSBERT	Director	Sep 10	Sale	29.04	5,931	172,236	7,668,518	Sep 13 06:22 PM
GADICKE ANSBERT	Director	Sep 10	Sale	29.04	820	23,813	247,350	Sep 13 06:22 PM
UBS Oncology Impact Fund L.P.	10% Owner	Sep 10	Sale	29.04	5,931	172,236	7,668,518	Sep 13 06:24 PM
UBS Oncology Impact Fund L.P.	10% Owner	Sep 09	Sale	29.35	13,727	402,887	7,674,449	Sep 13 06:24 PM
GADICKE ANSBERT	Director	Sep 09	Sale	29.35	13,727	402,887	7,674,449	Sep 13 06:22 PM
GADICKE ANSBERT	Director	Sep 09	Sale	29.35	1,898	55,706	248,170	Sep 13 06:22 PM
Trigilio Jeffrey	Chief Financial Officer	Sep 08	Option Exercise	4.30	15,000	64,500	17,250	Sep 09 04:15 PM
Baeuerle Patrick	See Remarks	Sep 08	Option Exercise	4.30	11,000	47,300	11,000	Sep 09 04:15 PM
Baeuerle Patrick	See Remarks	Sep 08	Sale	28.45	11,000	312,950	0	Sep 09 04:15 PM
Trigilio Jeffrey	Chief Financial Officer	Sep 08	Sale	28.48	15,000	427,153	2,250	Sep 09 04:15 PM
UBS Oncology Impact Fund L.P.	10% Owner	Sep 08	Sale	29.11	10,842	315,611	7,688,176	Sep 08 06:20 PM
GADICKE ANSBERT	Director	Sep 08	Sale	29.11	10,842	315,611	7,688,176	Sep 08 06:17 PM
GADICKE ANSBERT	Director	Sep 08	Sale	29.11	1,499	43,636	250,068	Sep 08 06:17 PM
Zawel Leigh	See Remarks	Sep 07	Sale	28.95	28,118	814,016	65,406	Sep 08 04:15 PM
GADICKE ANSBERT	Director	Sep 07	Sale	29.04	25,067	727,946	7,699,018	Sep 08 06:17 PM
GADICKE ANSBERT	Director	Sep 07	Sale	29.04	3,465	100,624	251,567	Sep 08 06:17 PM
UBS Oncology Impact Fund L.P.	10% Owner	Sep 07	Sale	29.04	25,067	727,946	7,699,018	Sep 08 06:20 PM
UBS Oncology Impact Fund L.P.	10% Owner	Sep 03	Sale	29.60	12,731	376,838	7,724,085	Sep 08 06:20 PM
GADICKE ANSBERT	Director	Sep 03	Sale	29.60	12,731	376,838	7,724,085	Sep 08 06:17 PM
GADICKE ANSBERT	Director	Sep 03	Sale	29.60	1,760	52,096	255,032	Sep 08 06:17 PM
GADICKE ANSBERT	Director	Sep 02	Sale	29.46	15,757	464,201	7,736,816	Sep 02 05:25 PM
GADICKE ANSBERT	Director	Sep 02	Sale	29.46	2,178	64,164	256,792	Sep 02 05:25 PM
UBS Oncology Impact Fund L.P.	10% Owner	Sep 02	Sale	29.46	15,757	464,201	7,736,816	Sep 02 05:26 PM
UBS Oncology Impact Fund L.P.	10% Owner	Sep 01	Sale	29.47	5,714	168,392	7,752,573	Sep 02 05:26 PM
GADICKE ANSBERT	Director	Sep 01	Sale	29.47	5,714	168,392	7,752,573	Sep 02 05:25 PM
GADICKE ANSBERT	Director	Sep 01	Sale	29.47	790	23,281	258,970	Sep 02 05:25 PM
GADICKE ANSBERT	Director	Aug 31	Sale	29.82	2,838	84,625	7,758,287	Sep 02 05:25 PM
GADICKE ANSBERT	Director	Aug 31	Sale	29.82	392	11,689	259,760	Sep 02 05:25 PM
UBS Oncology Impact Fund L.P.	10% Owner	Aug 31	Sale	29.82	2,838	84,625	7,758,287	Sep 02 05:26 PM
UBS Oncology Impact Fund L.P.	10% Owner	Aug 30	Sale	29.30	31,001	908,329	7,761,125	Aug 31 04:47 PM
GADICKE ANSBERT	Director	Aug 30	Sale	29.30	31,001	908,329	7,761,125	Aug 31 04:48 PM
GADICKE ANSBERT	Director	Aug 30	Sale	29.30	4,285	125,550	260,152	Aug 31 04:48 PM
GADICKE ANSBERT	Director	Aug 27	Sale	29.09	13,357	388,555	7,792,126	Aug 31 04:48 PM
GADICKE ANSBERT	Director	Aug 27	Sale	29.09	1,846	53,700	264,437	Aug 31 04:48 PM
UBS Oncology Impact Fund L.P.	10% Owner	Aug 27	Sale	29.09	13,357	388,555	7,792,126	Aug 31 04:47 PM
GADICKE ANSBERT	Director	Aug 25	Sale	29.09	1,713	49,831	7,805,483	Aug 25 07:41 PM
GADICKE ANSBERT	Director	Aug 25	Sale	29.09	237	6,894	266,283	Aug 25 07:41 PM
UBS Oncology Impact Fund L.P.	10% Owner	Aug 25	Sale	29.09	1,713	49,831	7,805,483	Aug 25 07:42 PM
UBS Oncology Impact Fund L.P.	10% Owner	Aug 24	Sale	29.48	50,822	1,498,233	7,807,196	Aug 25 07:42 PM
GADICKE ANSBERT	Director	Aug 24	Sale	29.48	50,882	1,500,001	7,807,196	Aug 25 07:41 PM
GADICKE ANSBERT	Director	Aug 24	Sale	29.48	7,025	207,097	266,520	Aug 25 07:41 PM
GADICKE ANSBERT	Director	Aug 23	Sale	29.11	53,359	1,553,280	7,858,018	Aug 25 07:41 PM
GADICKE ANSBERT	Director	Aug 23	Sale	29.11	7,376	214,715	273,545	Aug 25 07:41 PM
UBS Oncology Impact Fund L.P.	10% Owner	Aug 23	Sale	29.11	53,359	1,553,280	7,858,018	Aug 25 07:42 PM
Zawel Leigh	See Remarks	Aug 23	Sale	29.00	28,118	815,422	93,524	Aug 24 04:06 PM
Michaelson Jennifer	See Remarks	Aug 18	Option Exercise	4.30	4,000	17,200	26,911	Aug 24 04:06 PM
Michaelson Jennifer	See Remarks	Aug 18	Sale	27.66	4,000	110,648	22,911	Aug 24 04:06 PM
UBS Oncology Impact Fund L.P.	10% Owner	Aug 11	Sale	29.05	2,510	72,916	7,911,377	Aug 12 04:55 PM
GADICKE ANSBERT	Director	Aug 11	Sale	29.05	2,510	72,916	7,911,377	Aug 12 04:54 PM
GADICKE ANSBERT	Director	Aug 11	Sale	29.05	347	10,080	280,921	Aug 12 04:54 PM
Baeuerle Patrick	See Remarks	Aug 10	Option Exercise	4.30	11,000	47,300	11,000	Aug 26 07:11 PM
Baeuerle Patrick	See Remarks	Aug 10	Sale	27.00	11,000	297,000	0	Aug 26 07:11 PM
Zawel Leigh	See Remarks	Aug 10	Sale	27.41	6,914	189,517	121,642	Aug 11 04:15 PM
Zawel Leigh	See Remarks	Aug 09	Sale	26.57	21,204	563,333	128,556	Aug 11 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience